<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01805154</url>
  </required_header>
  <id_info>
    <org_study_id>60046199</org_study_id>
    <nct_id>NCT01805154</nct_id>
  </id_info>
  <brief_title>Advance Cardiac Resynchronization Therapy (CRT) Registry</brief_title>
  <official_title>Registry That Aims to Understand the Definition Used and Treatment Options Utilized by Clinicials for CRT Non-responders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The intent of this registry is to understand comprehensive clinical care strategies for
      Cardiac Resynchronization Therapy (CRT) patients especially non-responders in real-world
      clinical practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who are implanted CRT devices will be enrolled in the study. Once implanted, all
      patients will be followed at every 3 months for the first 12 months from the implant. The
      responder/non-responder evaluation will occur at 6 months from the implant date. The criteria
      used for determining the response to CRT will be captured.

      During the office follow-up visits, arrhythmic episode diagnoses, device data and stored
      electrogram will be collected. All clinical events such as hospitalization for heart failure
      (HF), all-cause hospitalizations, and all-cause death will also be collected. For patients
      who are non-responders to CRT, any re-optimization of the device, i.e., atrioventricular and
      ventricle-to-ventricle interval optimization, left ventricular (LV) lead repositioning and
      pacing vector reconfiguration as well as modified/new clinical therapies administered in an
      attempt to improve HF condition will be collected.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Number of CRT Non-responders Using 1) Clinical Composite Score (CCS) and 2) Site-specific Criteria for Determining CRT Response</measure>
    <time_frame>6 months</time_frame>
    <description>The CCS has 4 components: New York Heart Association (NYHA) functional classification, Patient Global Assessment (PGA), heart failure (HF) events, cardiovascular death. NYHA Class ranges from Class I (least severe) to Class IV (most severe); possible PGA responses are &quot;markedly worse&quot;, &quot;moderately worse&quot;, &quot;slightly worse&quot;, &quot;no change&quot;, &quot;slightly better&quot;, &quot;moderately better, &quot;markedly better&quot;. CCS components were used to classify or score subjects as &quot;IMPROVED&quot; (at least one-class improvement in NYHA Class or improvement by PGA &quot;moderately&quot; or &quot;markedly&quot; better AND no HF events AND no cardiovascular death), or &quot;WORSENED&quot; (worsening in NYHA Class OR worsening by PGA &quot;moderately&quot; or &quot;markedly&quot; worse OR presence of HF events OR Cardiovascular death, or &quot;UNCHANGED&quot; (neither &quot;improved&quot; or &quot;worsened&quot;). Note CCS is not a numeric score.
Sites used their own clinical criteria (could include hospitalizations, functional assessments, etc.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Specfic Types of Symptom-based and Objective Definitions Used by Sites to Determine Patients' Response to CRT</measure>
    <time_frame>6 months</time_frame>
    <description>Number of subjects where sites used echocardiographic remodeling, clinical functional assessments, or clinical events to determine response status.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects That Received Treatment Strategies for Heart Failure in the CRT Non-responder Population Between 6 and 12 Months</measure>
    <time_frame>Between 6 and 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Had an Improvement in NYHA Class Between Six Months and 12 Months</measure>
    <time_frame>Between 6 and 12 months</time_frame>
    <description>Improvement in NYHA Class determined by improvement by at least 1 class.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1529</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>CRT patients</arm_group_label>
    <description>Patients who have received any market approved St Jude Medical CRT-D or CRT-P device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CRT Patients</intervention_name>
    <description>This is a group of patients who are receiving bi-ventricular pacing therapy from CRT device.</description>
    <arm_group_label>CRT patients</arm_group_label>
    <other_name>St Jude Medical, Any approved CRT device</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HF patients with St. Jude Medical CRT devices
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient willing and able to sign informed consent

          -  Patients implanted with any market-approved St. Jude Medical CRT-D/P device with no
             prior LV lead placement

        Exclusion Criteria:

          -  Are likely to undergo heart transplantation within the next 12 months

          -  Are less than 18 years of age

          -  Are pregnant or planning to become pregnant during the duration of the study

          -  Are currently participating in a clinical investigation that includes an active
             treatment arm

          -  Have a life expectancy of less than 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niraj Varma, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Cardiovascular Group, P.C.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>*Heart Center Research, LLC.</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Consultants Ltd</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Associates of Mesa</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Cardiovascular Research Group</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Arizona VA Health Care System</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cardiovascular</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chula Vista Cardiac Center</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiac Rhythm Specialist</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Claudio Bonometti MD, Inc</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cardiac &amp; Vascular Institute Research Foundation, LLC</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Consultants - Baptist Campus</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tallahassee Research Institute</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center - Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Cardiovascular Center</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Health and Hospitals Corporation</name>
      <address>
        <city>Oakbrook Terrace</city>
        <state>Illinois</state>
        <zip>60181</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unitypoint</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Care Associates PSC</name>
      <address>
        <city>Madisonville</city>
        <state>Kentucky</state>
        <zip>42431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth's Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Consultants of East Michigan</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>*Thoracic Cardio Healthcare Found. (aka Sparrow Research)</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson Heart Clinic</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Associates of North Mississippi</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deborah Heart and Lung Center</name>
      <address>
        <city>Browns Mills</city>
        <state>New Jersey</state>
        <zip>08015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lourdes Cardiology Services</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis HealthCare System</name>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <zip>43701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Consultants in Cardiovascular Diseases</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain States Medical Group Cardiology</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knoxville Cardiovascular Research Group, LLC</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Texas Heart Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martha Jefferson</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiac Rhythm Specialists, S.C.</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cheyenne Cardiology Associates</name>
      <address>
        <city>Cheyenne</city>
        <state>Wyoming</state>
        <zip>82001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Favaloro para la Docencia e Inv. med.</name>
      <address>
        <city>Buenos Aires</city>
        <state>Riodepl</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Cardiovascular Buenos Aires (ICBA)</name>
      <address>
        <city>Buenos Aires</city>
        <state>Riodepl</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biocor Instituto</name>
      <address>
        <city>Nova Lima</city>
        <state>Minas</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Beneficiencia Portuguesa de Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <state>Sao Pau</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto do Coracao (InCor) - HCFMUSP</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guizhou Provincial People's Hospital</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Kunming Medical University</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 2nd Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APEX Foundation</name>
      <address>
        <city>Medellin</city>
        <state>Antioq</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delhi Heart and Lung Institute</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Escorts Heart Institute and Research Centre</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fortis Flt. Lt. Rajan Dhall Hospital</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Institute of Medical Sciences</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Family Hospital and Medical Research Center</name>
      <address>
        <city>Mumbai</city>
        <state>Mhrshtr</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruby Hall Clinic</name>
      <address>
        <city>Pune</city>
        <state>Mhrshtr</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medanta - The Medicity Hospital</name>
      <address>
        <city>Gurgaon</city>
        <state>Nct Dlh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fortis Escorts Hospital</name>
      <address>
        <city>Amritsar</city>
        <state>Punjab</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fortis Hospital</name>
      <address>
        <city>Mohali</city>
        <state>Punjab</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Madras Medical Mission</name>
      <address>
        <city>Chennai</city>
        <state>Tmlnadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujita Health University School of medicine</name>
      <address>
        <city>Toyoake</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hirosaki University Hospital</name>
      <address>
        <city>Hirosaki-shi</city>
        <state>Aomori</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokura Memorial Hospital</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka Prefecture</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiba University</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eulji university Hospital Daejeon</name>
      <address>
        <city>Daejeon</city>
        <state>Hoseo</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Sudogwn</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <state>Sudogwn</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Rhythm Management</name>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>China</country>
    <country>Colombia</country>
    <country>India</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>February 14, 2013</study_first_submitted>
  <study_first_submitted_qc>March 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2013</study_first_posted>
  <results_first_submitted>October 23, 2018</results_first_submitted>
  <results_first_submitted_qc>July 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 12, 2019</results_first_posted>
  <last_update_submitted>July 1, 2019</last_update_submitted>
  <last_update_submitted_qc>July 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 17, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT01805154/Prot_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cardiac Resynchronization Therapy Patients</title>
          <description>Patients who have received any market approved St Jude Medical cardiac resynchronization therapy defibrillator (CRT-D) or cardiac resynchronization therapy pacemaker (CRT-P) device.
Cardiac resynchronization therapy patients: This is a group of patients who are receiving bi-ventricular pacing therapy from cardiac resynchronization therapy device.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1529"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1175"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="354"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Of 1529 subjects enrolled, 5 were not included in baseline analyses (1 subject had incomplete informed consent and 4 did not have a device implant). Thus, only 1524 subjects were evaluable.</population>
      <group_list>
        <group group_id="B1">
          <title>CRT Patients</title>
          <description>Patients who have received any market approved St Jude Medical CRT-D or CRT-P device
CRT Patients: This is a group of patients who are receiving bi-ventricular pacing therapy from a CRT device.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1524"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1524"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.9" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1524"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="480"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>Information was provided by 1428 subjects</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/Ethnic category</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1428"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="327"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White or Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="883"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Colombia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1524"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1524"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1524"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1524"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>New York Heart Association (NYHA) Class</title>
          <description>NYHA Functional Classification has 4 categories:
Class I (least severe) - no limitation of physical activity Class II - slight limitation of physical activity Class III - marked limitation of physical activity Class IV (most severe) - unable to carry on any physical activity without discomfort</description>
          <population>information was available on 1522 subjects</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1522"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>NYHA Class I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA Class II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="335"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA Class III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1033"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA Class IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of Cardiomyopathy</title>
          <population>Information was available on 1518 subjects</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1518"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Ischemic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="597"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-Ischemic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="709"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left Ventricular Ejection Fraction % (EF)</title>
          <description>This is % of blood ejected from the left ventricle</description>
          <population>Information was available on 1521 subjects</population>
          <units>Percent blood ejected</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1521"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.2" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Atrial Fibrillation (AF)</title>
          <population>Information was available on 1518 subjects</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1518"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of CRT Non-responders Using 1) Clinical Composite Score (CCS) and 2) Site-specific Criteria for Determining CRT Response</title>
        <description>The CCS has 4 components: New York Heart Association (NYHA) functional classification, Patient Global Assessment (PGA), heart failure (HF) events, cardiovascular death. NYHA Class ranges from Class I (least severe) to Class IV (most severe); possible PGA responses are &quot;markedly worse&quot;, &quot;moderately worse&quot;, &quot;slightly worse&quot;, &quot;no change&quot;, &quot;slightly better&quot;, &quot;moderately better, &quot;markedly better&quot;. CCS components were used to classify or score subjects as &quot;IMPROVED&quot; (at least one-class improvement in NYHA Class or improvement by PGA &quot;moderately&quot; or &quot;markedly&quot; better AND no HF events AND no cardiovascular death), or &quot;WORSENED&quot; (worsening in NYHA Class OR worsening by PGA &quot;moderately&quot; or &quot;markedly&quot; worse OR presence of HF events OR Cardiovascular death, or &quot;UNCHANGED&quot; (neither &quot;improved&quot; or &quot;worsened&quot;). Note CCS is not a numeric score.
Sites used their own clinical criteria (could include hospitalizations, functional assessments, etc.)</description>
        <time_frame>6 months</time_frame>
        <population>The analysis population included any subject who had a 6-month CRT evaluation or died due to a cardiovascular cause prior to 6 months. Subjects who withdrew prior to the 6-month visit, did not complete the 6-month visit or had relevant 6-month data missing were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CRT Patients</title>
            <description>Patients who received any market approved St. Jude Medical CRT-D or CRT-P device.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of CRT Non-responders Using 1) Clinical Composite Score (CCS) and 2) Site-specific Criteria for Determining CRT Response</title>
          <description>The CCS has 4 components: New York Heart Association (NYHA) functional classification, Patient Global Assessment (PGA), heart failure (HF) events, cardiovascular death. NYHA Class ranges from Class I (least severe) to Class IV (most severe); possible PGA responses are &quot;markedly worse&quot;, &quot;moderately worse&quot;, &quot;slightly worse&quot;, &quot;no change&quot;, &quot;slightly better&quot;, &quot;moderately better, &quot;markedly better&quot;. CCS components were used to classify or score subjects as &quot;IMPROVED&quot; (at least one-class improvement in NYHA Class or improvement by PGA &quot;moderately&quot; or &quot;markedly&quot; better AND no HF events AND no cardiovascular death), or &quot;WORSENED&quot; (worsening in NYHA Class OR worsening by PGA &quot;moderately&quot; or &quot;markedly&quot; worse OR presence of HF events OR Cardiovascular death, or &quot;UNCHANGED&quot; (neither &quot;improved&quot; or &quot;worsened&quot;). Note CCS is not a numeric score.
Sites used their own clinical criteria (could include hospitalizations, functional assessments, etc.)</description>
          <population>The analysis population included any subject who had a 6-month CRT evaluation or died due to a cardiovascular cause prior to 6 months. Subjects who withdrew prior to the 6-month visit, did not complete the 6-month visit or had relevant 6-month data missing were excluded from the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Site Determined CRT Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CCS Deteremined CRT Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Specfic Types of Symptom-based and Objective Definitions Used by Sites to Determine Patients' Response to CRT</title>
        <description>Number of subjects where sites used echocardiographic remodeling, clinical functional assessments, or clinical events to determine response status.</description>
        <time_frame>6 months</time_frame>
        <population>The analysis population included any subject with a completed 6-month CRT evaluation. Subjects who withdrew prior to the 6-month visit, did not complete the 6-month visit or had relevant 6-month data missing were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CRT Patients</title>
            <description>Patients who received any market approved St. Jude Medical CRT-D or CRT-P device.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Specfic Types of Symptom-based and Objective Definitions Used by Sites to Determine Patients' Response to CRT</title>
          <description>Number of subjects where sites used echocardiographic remodeling, clinical functional assessments, or clinical events to determine response status.</description>
          <population>The analysis population included any subject with a completed 6-month CRT evaluation. Subjects who withdrew prior to the 6-month visit, did not complete the 6-month visit or had relevant 6-month data missing were excluded from the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Echocardiographic Remodeling Used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Functional Assessment Used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Events Used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="858"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects That Received Treatment Strategies for Heart Failure in the CRT Non-responder Population Between 6 and 12 Months</title>
        <time_frame>Between 6 and 12 months</time_frame>
        <population>The analysis population included any subject with a completed 6-month CRT evaluation. Subjects who withdrew prior to the 6-month visit, did not complete the 6-month visit or had relevant 6-month data missing were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CRT Patients</title>
            <description>Patients who have received any market approved St. Jude Medical CRT-D or CRT-P device</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects That Received Treatment Strategies for Heart Failure in the CRT Non-responder Population Between 6 and 12 Months</title>
          <population>The analysis population included any subject with a completed 6-month CRT evaluation. Subjects who withdrew prior to the 6-month visit, did not complete the 6-month visit or had relevant 6-month data missing were excluded from the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Device LV Pacing Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Device AV/VV Intervals Optimized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Device Parameters Changed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medication Changed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arrythmia Treatments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diet Compliance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medication Compliance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HF Education Provided</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Treatments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment for Comorbidities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bi-Ventricular Pacing Increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Had an Improvement in NYHA Class Between Six Months and 12 Months</title>
        <description>Improvement in NYHA Class determined by improvement by at least 1 class.</description>
        <time_frame>Between 6 and 12 months</time_frame>
        <population>Only subjects who had evaluable data at 6 and 12 months are included. Thus, fewer subjects than those who completed the 6-month and 12-month visits were analyzable.</population>
        <group_list>
          <group group_id="O1">
            <title>Site CRT Responders</title>
            <description>Patients who have received any market approved St Jude Medical CRT-D or CRT-P device
CRT Patients: This is a group of patients who are receiving bi-ventricular pacing therapy from CRT device and were classified as CRT responders at 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Site CRT Non-Responders</title>
            <description>Patients who have received any market approved St Jude Medical CRT-D or CRT-P device
CRT Patients: This is a group of patients who are receiving bi-ventricular pacing therapy from CRT device and were classified as CRT non-responders at 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Had an Improvement in NYHA Class Between Six Months and 12 Months</title>
          <description>Improvement in NYHA Class determined by improvement by at least 1 class.</description>
          <population>Only subjects who had evaluable data at 6 and 12 months are included. Thus, fewer subjects than those who completed the 6-month and 12-month visits were analyzable.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="559"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data were collected and reported over the 12-month study period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CRT Patients</title>
          <description>Patients who have received any market approved St Jude Medical CRT-D or CRT-P device CRT Patients: This is a group of patients who are receiving bi-ventricular pacing therapy from CRT device.
Of 1529 subjects enrolled, 5 were not included in analysis (1 had incomplete informed consent and 4 did not receive a device implant).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="226" subjects_at_risk="1524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute CHF</sub_title>
                <counts group_id="E1" events="102" subjects_affected="70" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>Atrial Arrythmia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>Atrial Fib Ablation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>NEW OR WORSENED ANGINA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>OTHER Cardiac</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>OTHER Death</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>VENTRICULAR ARRHYTHMIA</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>WORSENING CAD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>OTHER Gastro</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>HOSPITALIZATION FOR DECREASED MENTAL STATUS AND FEVER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>OTHER General</sub_title>
                <counts group_id="E1" events="43" subjects_affected="37" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>SOB; EDEMA; DIURESIS; MONITORING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>SYNCOPE UNKNOWN ETIOLOGY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>THROMBO-EMBOLIC EVENT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>EROSION/EXTRUSION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>OTHER Infections</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="1524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Air Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>Arrest Cardiopulmonary</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>BLEEDING(NON-HEMATOMA)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>CARDIAC TAMPONADE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>CARDIAC/CORONARY SINUS DISSECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>ER VISIT AND OBSERVATION ADMISSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>HEMATOMA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>LEAD DISLODGEMENT OR MIGRATION</sub_title>
                <counts group_id="E1" events="51" subjects_affected="41" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>PHRENIC NERVE/DIAPHRAGMATIC STIMULATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>SHOCK/HYPOTENSION</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="1524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>TRIMALLEOLAR FRACTURE RIGHT ANKLE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>RA LEAD FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>RV LEAD MALFUNCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>LV LOSS OF CAPTURE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>PULSE GENERATOR MALFUNCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Other Respiratory</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="403" subjects_at_risk="1524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>ARREST - CARDIOPULMONARY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>ASYSTOLE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>ATRIAL ARRHYTHMIA</sub_title>
                <counts group_id="E1" events="39" subjects_affected="37" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>DECOMPENSATED HF</sub_title>
                <counts group_id="E1" events="133" subjects_affected="98" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>HEART FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>LOW CARDIAC OUTPUT SYNDROME AND PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>NEW OR WORSENED ANGINA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>OTHER Cardiac</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>THERAPY FOR NON-VENTRICULAR RHYTHM</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>VENTRICULAR ARRHYTHMIA</sub_title>
                <counts group_id="E1" events="51" subjects_affected="7" subjects_at_risk="1524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CLOSTRIDIUM DIAARHEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>OTHER Gastro</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="1524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>DIZZINESS, NAUSEA, IRREGULAR HEART BEAT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>OTHER General</sub_title>
                <counts group_id="E1" events="284" subjects_affected="174" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>SYNCOPE UNKNOWN ETIOLOGY</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>THROMBO-EMBOLIC EVENT</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" events="26" subjects_affected="25" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>OTHER Infections</sub_title>
                <counts group_id="E1" events="53" subjects_affected="37" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>SHOCK/HYPOTENSION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>UPPER RESIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>BLEEDING(NON-HEMATOMA)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>HEMATOMA</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>HEMOTHORAX</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>LEAD DISLODGEMENT OR MIGRATION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>OTHER Implant</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>ELEVATED PACING THRESHOLDS</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>HIGH DFT'S</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>Lead Noise</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>LOSS OF CAPTURE</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>LOSS OF SENSING</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>OVERSENSING</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>OVERSENSING RESULTING IN THERAPY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>PACEMAKER MEDIATED TACHYCARDIA (PMT)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>PHRENIC NERVE/DIAPHRAGMATIC STIMULATION</sub_title>
                <counts group_id="E1" events="38" subjects_affected="33" subjects_at_risk="1524"/>
              </event>
              <event>
                <sub_title>UNDERSENSING</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Other Respiratory</sub_title>
                <counts group_id="E1" events="23" subjects_affected="18" subjects_at_risk="1524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>LOWER EXTREMITY EDEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1524"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clay Cohorn, Clinical Program Director</name_or_title>
      <organization>Abbott</organization>
      <phone>972-309-8087</phone>
      <email>clay.cohorn@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

